In patients with liver metastases, Kisqali combination therapy cut the risk of death by 47% and 37% in two trialsOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.